Details

Targeting neuroinflammation and cognitive decline : first-in-class dual butyrylcholinesterase and p38α mitogen-activated protein kinase inhibitors
ID Ferjančič Benetik, Svit (Author), ID Proj, Matic (Author), ID Knez, Damijan (Author), ID Košak, Urban (Author), ID Meden, Anže (Author), ID Krajšek, Katja (Author), ID Pišlar, Anja (Author), ID Horvat, Selena (Author), ID Obreza, Aleš (Author), ID Gobec, Stanislav (Author), et al.

.pdfPDF - Presentation file, Download (8,94 MB)
MD5: A25F629905E43F00581813868B51E48A
URLURL - Source URL, Visit https://pubs.acs.org/doi/10.1021/acs.jmedchem.5c00933 This link opens in a new window

Abstract
The currently approved drugs for the treatment of Alzheimer’s disease (AD) fail to address its interconnected pathological processes. Inhibition of butyrylcholinesterase (BChE) and p38α mitogen-activated protein kinase (p38α MAPK) offers an innovative dual approach to mitigate two major drivers of neurodegeneration in AD: cholinergic deficit and neuroinflammation. Using structure-based drug design and a library of known p38α MAPK inhibitors, we developed first-in-class, selective dual BChE/p38α MAPK inhibitors with balanced activity against both targets. The X-ray crystal structures of the two most promising molecules bound to both enzymes were solved. Those ligands effectively reduced the production of proinflammatory markers in vitro and ex vivo in phytohemagglutinin/lipopolysaccharide neuroinflammation models. Remarkably, these compounds also significantly improved cognition in scopolamine- and lipopolysaccharide-induced models of cognitive dysfunction in mice. Because our dual-acting inhibitors target both the symptoms and the underlying neuropathology, they offer an innovative and comprehensive strategy to combat AD.

Language:English
Keywords:central nervous system, inhibition, inhibitors, peptides and proteins, rodent models
Work type:Article
Typology:1.01 - Original Scientific Article
Organization:FFA - Faculty of Pharmacy
Publication status:Published
Publication version:Version of Record
Year:2025
Number of pages:Str. 17378−17411
Numbering:Vol. 68, iss. 16
PID:20.500.12556/RUL-175854 This link opens in a new window
UDC:615.4:54:616.894
ISSN on article:1520-4804
DOI:10.1021/acs.jmedchem.5c00933 This link opens in a new window
COBISS.SI-ID:250778371 This link opens in a new window
Publication date in RUL:11.11.2025
Views:139
Downloads:33
Metadata:XML DC-XML DC-RDF
:
Copy citation
Share:Bookmark and Share

Record is a part of a journal

Title:Journal of medicinal chemistry
Shortened title:J. med. chem.
Publisher:American Chemical Society
ISSN:1520-4804
COBISS.SI-ID:512806681 This link opens in a new window

Licences

License:CC BY 4.0, Creative Commons Attribution 4.0 International
Link:http://creativecommons.org/licenses/by/4.0/
Description:This is the standard Creative Commons license that gives others maximum freedom to do what they want with the work as long as they credit the author.

Secondary language

Language:Slovenian
Keywords:centralni živčni sistem, inhibicija, inhibitorji, peptidi in beljakovine, modeli glodalcev, farmacevtska kemija, Alzheimerjeva bolezen

Projects

Funder:NCN - National Science Centre
Project number:DEC-2021/43/I/NZ7/00342

Funder:GAČR - Czech Science Foundation
Project number:GF23-42701L

Funder:ARIS - Slovenian Research and Innovation Agency
Project number:N1-0277
Name:Raziskave multifunkcionalnih spojin, usmerjenih proti nevroinflamaciji in holinergičnemu pomanjkanju pri Alzheimerjevi bolezni

Funder:ARIS - Slovenian Research and Innovation Agency
Project number:P1-0208
Name:Farmacevtska kemija: načrtovanje, sinteza in vrednotenje učinkovin

Funder:ARIS - Slovenian Research and Innovation Agency
Funding programme:Young researchers

Funder:France, Ministry of Armed Forces
Project number:DGA/SSA NBC-5-C-2316

Similar documents

Similar works from RUL:
Similar works from other Slovenian collections:

Back